ALDH16A1 Knockout HEK293T Polyclonal Cells offer a CRISPR/Cas9-engineered loss-of-function model targeting ALDH16A1, which encodes a member of the aldehyde dehydrogenase superfamily that catalyzes the oxidation of aldehydes to carboxylic acids. The polyclonal knockout population is generated by delivering Cas9 and guide RNAs into HEK293T cells, resulting in a heterogeneous collection of edits that collectively abolish ALDH16A1 function. This format is ideal for studying bulk cellular phenotypes without clonal bias and provides a reliable system for downstream functional assays.
HEK293T is a human embryonic kidney epithelial cell line stably expressing the SV40 large T antigen, derived from the parental HEK293 line. These cells are widely recognized for their high transfection efficiency, robust protein expression capacity, and utility in producing lentiviral and adeno-associated viral vectors. The epithelial origin, rapid proliferation rate, and genetic tractability of HEK293T make it a preferred host for generating knockout models, particularly for interrogating metabolic enzymes and signaling pathways in a simplified cellular context.
At the molecular level, ALDH16A1 participates in aldehyde detoxification and is linked to aldehyde metabolism, protein degradation, and androgen receptor signaling. The encoded enzyme interacts with huntingtin-interacting protein 1 (HIP1), an endocytic adaptor protein implicated in receptor internalization and trafficking. This interaction positions ALDH16A1 at the interface of metabolic and signaling networks. Epidemiological and genetic association studies have identified ALDH16A1 variants as risk factors for gout and prostate cancer, suggesting that its enzymatic activity influences urate homeostasis and androgen-dependent growth pathways. Although detailed upstream regulatory mechanisms remain to be fully elucidated, the functional connection to HIP1 provides a foundation for exploring its role in cellular signaling.
Within the HEK293T background, ALDH16A1 knockout enables the dissection of its intrinsic biochemical and signaling functions decoupled from tissue-specific variables. The polyclonal nature of the knockout population offers a cost-effective and representative model for compound screening, as it captures a range of editing efficiencies and mimics the diversity of therapeutic responses. This setting is particularly useful for investigating the crosstalk between aldehyde metabolism and androgen receptor pathways, as well as for assessing the impact of ALDH16A1 loss on apoptotic signaling. Researchers can also introduce exogenous ALDH16A1 variants to validate disease-associated mutations in a controlled isogenic context.
This product supports diverse research applications, including functional characterization of ALDH16A1 in aldehyde metabolism, mechanistic studies of its interaction with HIP1, and investigation into its roles in gout and prostate cancer. Frequently employed assays include western blotting and RT-qPCR for verifying knockout efficiency, aldehyde dehydrogenase activity measurements using spectrophotometric or fluorescence-based methods, co-immunoprecipitation to probe protein complexes, and flow cytometric analysis of apoptosis and cell cycle perturbations. The polyclonal knockout cells are also compatible with high-throughput drug screening platforms seeking to identify or evaluate modulators of ALDH16A1 activity. For further details, please contact Ascent Research.
